Search results (574)
« Back to Publicationsligning Approaches to Rheumatoid Arthritis Drug Development: An Expert Comparison of FDA and EMA Guidance
Journal article
Ciancio A. et al, (2026), The Lancet Rheumatology
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies
Journal article
Baraliakos X. et al, (2026), Rheumatology and Therapy
Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence
Journal article
Tanaka Y. et al, (2026), Rheumatology and Therapy
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease modifying antirheumatic drugs: 2025 update
Journal article
Smolen JS. et al, (2026), Annals of the Rheumatic Diseases
Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies: Results From the Phase 2a DAISY-RA Study
Journal article
Taylor PC. et al, (2026), RMD Open
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.
Journal article
Smolen JS. et al, (2026), RMD Open, 12
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.
Journal article
Taylor PC. et al, (2026), RMD Open, 12
The positive perspective paradigm: proposal of a model to mitigate the impact of chronic inflammatory arthritis through comprehensive and early intervention
Journal article
Doumen M. et al, (2026), Annals of the Rheumatic Diseases
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis.
Journal article
Triaille C. et al, (2026), Lancet Rheumatol, 8, e66 - e73
Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition.
Journal article
Taylor PC. et al, (2025), BMC Med, 23
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis
Journal article
Triaille C. et al, (2025), Lancet Rheumatology
IL-23 drives uveitis by acting on a population of tissue-resident entheseal T cells.
Journal article
Hedley R. et al, (2025), JCI Insight, 10
Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Journal article
Taylor PC. et al, (2025), Adv Ther, 42, 4717 - 4719
Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis.
Journal article
Lewis MJ. et al, (2025), Nat Commun, 16
STAT3 phosphorylation in the rheumatoid arthritis immunological synapse.
Journal article
Novak-Kotzer H. et al, (2025), J Autoimmun, 155